NCT03048500View on ClinicalTrials.gov

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

PHASE2UnknownINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 12, 2017

Primary Completion Date

September 19, 2019

Study Completion Date

September 30, 2021

Conditions
Recurrent Non-Small Cell Lung CarcinomaStage III Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Metformin Hydrochloride

Given PO

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (2)

60045

Northwestern University- Lake Forest Hospital, Lake Forest

60611

Northwestern University, Chicago

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER